CHAPTER 1 - MARKET SUMMARY
Market Overview
The Thailand Veterinary Pharmaceuticals Market serves two structurally different demand systems: intensive food-animal production and veterinary care for companion animals. In 2025, Thailand recorded approximately 500.8 million chickens, 12.2 million pigs and 9.54 million beef cattle. Recurring vaccination, parasite control and therapeutic requirements therefore translate animal inventories into repeat pharmaceutical consumption, particularly across integrated poultry, swine and ruminant operations.
Bangkok Metropolitan Region is the principal commercial, regulatory and distribution hub, while pharmaceutical consumption extends into major livestock-producing provinces. The observable national animal-health supplier ecosystem comprises 79 member companies involved in veterinary drugs and related products. Concentration of multinational affiliates, regulatory teams and distributors around Bangkok makes inventory availability, cold-chain execution and nationwide technical-service reach important competitive differentiators.
Market Value
USD 403 million
2025
Dominant Region
Bangkok Metropolitan Region
2025
Dominant Segment
Food-Producing Poultry
fastest growing: Companion Animals, 2025
Total Number of Players
79
2025
Future Outlook
The Thailand Veterinary Pharmaceuticals Market is projected to advance from USD 403 million in 2025 to USD 718 million by 2032, representing an 8.60% CAGR. This forecast exceeds the 6.80% historical CAGR recorded during 2020-2025 as preventive medicine, biologics and companion-animal therapeutics contribute more strongly to incremental revenue. The model reaches approximately USD 661 million in 2031 before closing at the 2032 terminal value. Livestock pharmaceuticals remain foundational, but a progressively larger share of growth comes from differentiated formulations, vaccines and specialty products rather than purely from higher treatment volumes.
Value growth is expected to outpace treatment-equivalent volume growth as product mix migrates toward preventive biologics and premium therapeutics. Companion-animal revenue is modelled to increase from 29.0% of the market in 2025 to 38.0% by 2032, while vaccines and immunologicals increase from 25.0% to 31.0%. The forecast assumes continued disease-prevention requirements, stable access to imported biologics, disciplined regulatory review and stronger veterinary care expenditure. An independent broader veterinary-medicine benchmark places Thailand at approximately USD 429 million in 2025, supporting the scale of the locked estimate after scope normalization.
8.60%
Forecast CAGR
$718 Mn
2030 Projection
Base Year
2025
Historical Period
2020-2025
Forecast Period
2025-2032
Historical CAGR
6.80%
CHAPTER 2 - SCOPE OF REPORT
Scope of the Market
CHAPTER 3 - Key Stakeholders
Key Target Audience
Key stakeholders who can leverage from this market analysis for investment, strategy, and operational planning.
Investors
forecast CAGR, biologics mix, working capital, regulatory risk, consolidation
Corporates
portfolio registration, cold-chain fill rates, distributor coverage, farm access
Government
AMR stewardship, vaccine coverage, biosecurity, import dependence, traceability
Operators
dose compliance, inventory availability, cold-chain integrity, technical field support
Financial institutions
receivables cycle, import exposure, inventory finance, demand resilience
CHAPTER 4 - Market Size & Growth
Market Size, Growth Forecast and Trends
This section evaluates the historical market size, analyzes year-over-year growth dynamics, and presents forecast projections supported by market performance indicators and demand-side drivers.
Historical & Projected Market Size ($ Million)
Year-over-Year Growth Rate (%)
Market Value vs Volume Growth (%)
Historical Market Performance (2020-2025)
Historical performance shows an early slowdown followed by sustained normalization. YoY growth reached its trough at 3.79% in 2021 before strengthening to 7.64% in 2022, 7.72% in 2023 and 7.74% in 2024. The treatment-equivalent volume index increased from 100.0 in 2020 to 124.3 in 2025, equivalent to approximately 4.45% annualized volume growth. The difference between value and volume expansion indicates a positive price and portfolio-mix effect as preventive products, branded therapies and companion-animal pharmaceuticals gained commercial importance.
Forecast Market Outlook (2025-2032)
The forecast closes at USD 718 million in 2032, with an 8.60% CAGR from the 2025 base. Treatment-equivalent volume is modelled to reach 184.9 by 2032, implying materially faster utilization than during the historical period. Value growth remains higher than volume growth because vaccines, immunologicals and specialty therapies gain mix. The model does not require aggressive price inflation: annual mix and pricing contribution remains around 2.6 to 2.9 percentage points, while underlying treatment activity benefits from livestock biosecurity, pet healthcare intensity and recurring vaccination protocols.
CHAPTER 5 - Market Data
Market Breakdown
The Thailand Veterinary Pharmaceuticals Market is transitioning from a predominantly high-volume livestock treatment pool toward a more balanced combination of production-animal medicines, preventive biologics and premium companion-animal therapeutics. This mix shift increases strategic relevance for manufacturers with regulatory depth, cold-chain execution and differentiated portfolios.
Year | Market Size (USD Mn) | YoY Growth (%) | Companion Animal Revenue Mix (%) | Vaccines & Immunologicals Revenue Mix (%) | Treatment-Equivalent Volume Index (2020=100) | Period |
|---|---|---|---|---|---|---|
| 2020 | $290 Mn | +- | 21.0% | 21.0% | Forecast | |
| 2021 | $301 Mn | +3.79% | 22.0% | 21.8% | Forecast | |
| 2022 | $324 Mn | +7.64% | 23.5% | 22.6% | Forecast | |
| 2023 | $349 Mn | +7.72% | 25.0% | 23.5% | Forecast | |
| 2024 | $376 Mn | +7.74% | 27.0% | 24.2% | Forecast | |
| 2025 | $403 Mn | +7.18% | 29.0% | 25.0% | Forecast | |
| 2026 | $438 Mn | +8.68% | 30.2% | 25.8% | Forecast | |
| 2027 | $475 Mn | +8.45% | 31.5% | 26.6% | Forecast | |
| 2028 | $516 Mn | +8.63% | 32.8% | 27.4% | Forecast | |
| 2029 | $561 Mn | +8.72% | 34.1% | 28.3% | Forecast | |
| 2030 | $609 Mn | +8.56% | 35.4% | 29.2% | Forecast | |
| 2031 | $661 Mn | +8.54% | 36.7% | 30.1% | Forecast | |
| 2032 | $718 Mn | +8.62% | 38.0% | 31.0% | Forecast |
Companion Animal Revenue Mix
5.38 million owned pets, 2025, Thailand. A larger and increasingly medicalized pet population expands the addressable pool for vaccines, dermatology, pain management and chronic therapies. Owned dogs reached 3.45 million and cats 1.94 million in 2025.
Vaccines & Immunologicals Revenue Mix
3 FMD virus types, 2025, Thailand. Thailand recognizes FMD types O, A and Asia I, with cattle vaccination followed by six-month boosters. Recurrent disease-prevention protocols support biologics demand and reward reliable cold-chain availability.
Treatment-Equivalent Volume Index
21.84 million tonnes feed demand, 2025, Thailand. Commercial feed demand rose 3.46%, with broilers accounting for 38.79% and fattening swine 24.28%. The scale signals intensive animal production requiring recurring veterinary health programs.
CHAPTER 6 - Segmentation
Market Segmentation Framework
Comprehensive analysis across key dimensions providing insights into market structure, consumer preferences, and distribution patterns.
No of Segments
7
Dominant Segment
Animal Type
Fastest Growing Segment
Product Type
Product Type
Animal Type
Distribution Channel
Formulation
Therapeutic Area
End User
Geography
Key Segmentation Takeaways
Comprehensive analysis across all extracted segmentation dimensions providing insights into market structure, consumer preferences, and distribution patterns.
Animal Type
Animal Type is commercially dominant because veterinary pharmaceutical demand is fundamentally determined by species inventories, disease exposure, dosing protocols and production economics. Food-Producing Poultry is the largest Level-2 demand pool given Thailand's very large broiler, layer and breeder base, while Food-Producing Mammals add recurring swine and ruminant demand. Companion Animals represent the principal premiumization pathway.
Product Type
Product Type is the fastest-growing strategic dimension as preventive medicine captures a larger share of pharmaceutical expenditure. Vaccines & Immunologicals are expected to lead incremental growth because disease-control programs require recurring administration, cold-chain execution and technical support. Anti-infectives remain important but face stewardship pressure, while parasiticides and specialty therapies benefit from differentiated efficacy and companion-animal care intensity.
CHAPTER 7 - Regional Analysis
Regional Analysis
Thailand ranks among Southeast Asia's larger veterinary-pharmaceutical markets when peer estimates are normalized to a common pharmaceutical and biologic scope. Indonesia remains larger by absolute revenue, while Thailand combines intensive livestock production, developed animal-health distribution and a faster companion-animal premiumization cycle, positioning it as an attractive regional growth market. kenresearch.com
Focus Country Ranking
2nd
Focus Country Market Size
USD 403 Mn (2025)
Thailand CAGR (2025-2032)
8.60%
Focus Country Ranking
2nd
Focus Country Market Size
USD 403 Mn (2025)
Thailand CAGR (2025-2032)
8.60%
Regional Analysis (Current Year)
Regional Analysis Comparison
| Metric | Indonesia | Thailand | Vietnam | Philippines | Malaysia |
|---|---|---|---|---|---|
| Market Size (USD Mn, 2025) | 455 | 403 | 185 | 170 | 115 |
| CAGR (%) (2025-2032) | 7.20% | 8.60% | 7.90% | 6.70% | 6.30% |
| Broad Animal-Health Demand Proxy (USD Mn, 2025) | 479 | 429 | 200 | 181 | 121 |
| Supply / Policy-Side KPI | Large livestock demand base with regulated veterinary-product imports and domestic distribution | Chemical and biologic registration routes with livestock-health oversight and vaccine controls | National veterinary drug registration supporting imported and domestic animal-health supply | Registered importer and distributor structure serving livestock and companion-animal channels | National veterinary-product regulation with branded import and distributor participation |
Market Position
Thailand ranks 2nd among five selected peers with a scope-normalized USD 403 Mn market in 2025, behind Indonesia at USD 455 Mn and ahead of Vietnam, the Philippines and Malaysia. kenresearch.com
Growth Advantage
Thailand's 8.60% CAGR leads the peer set, ahead of Vietnam at 7.90% and Indonesia at 7.20%, reflecting stronger biologics and companion-animal value-mix expansion. kenresearch.com
Competitive Strengths
Thailand combines approximately 500.8 million chickens, substantial swine and cattle populations, and an observable 79-company animal-health supplier ecosystem, supporting diversified demand and nationwide pharmaceutical distribution.
CHAPTER 8 - INDUSTRY ANALYSIS
Growth Drivers, Challenges & Opportunities
Comprehensive analysis of key factors shaping the Thailand Veterinary Pharmaceuticals Market, including growth catalysts, operational challenges, and emerging opportunities across production, distribution, and consumer segments.
Growth Drivers
Commercial Livestock Intensity Sustains Recurring Treatment Demand
- Broiler operations consumed 8.47 million tonnes of feed (2025, Thailand), representing 38.79% of national feed demand. High flock throughput makes preventive vaccination, anti-infective stewardship and rapid disease-response products economically important to integrators and pharmaceutical suppliers.
- Fattening swine required 5.30 million tonnes of feed (2025, Thailand), or 24.28% of demand, with feed volumes increasing 9.89%. Higher production intensity increases the economic cost of disease, supporting recurring spend on vaccines, parasiticides and prescription therapeutics.
- Layer-hen production accounted for 2.28 million tonnes of feed (2025, Thailand), equal to 10.43% of demand. Long production cycles increase the value of flock health, disease prevention and consistent medicine availability for producers, distributors and technical-service teams.
Companion-Animal Healthcare Premiumization
- Owned animals included approximately 3.45 million dogs and 1.94 million cats (2025, Thailand). This installed pet base creates recurring demand for vaccination, parasite control, dermatology, pain management and chronic-disease pharmaceuticals dispensed through hospitals and clinics.
- Animal-hospital business activity was projected to grow approximately 17% year on year (2025, Thailand). Greater clinical utilization increases prescription touchpoints, benefiting branded therapeutics, specialty medicines and manufacturers with strong veterinary education and clinic-channel capabilities.
- An independent benchmark places pet medicine at approximately USD 117 million (2025, Thailand). The scale validates companion animals as a meaningful pharmaceutical profit pool rather than a niche adjunct to production-animal demand.
Preventive Biologics and Disease-Control Requirements
- Thailand recognizes 3 epidemiologically relevant FMD virus types (2025, Thailand): O, A and Asia I. Serotype-specific immunity raises the technical importance of vaccine matching, monitoring and reliable biologic portfolios for ruminant producers.
- The official FMD vaccine guidance specifies a 2-dose primary sequence (2025 protocol, Thailand) before recurring boosters. Multi-dose prevention increases treatment-equivalent consumption and favors suppliers capable of maintaining cold-chain continuity and farm-level technical support.
- A national seminar on autogenous vaccines brought together 120 participants (2025, Thailand) from government, veterinary and private-sector stakeholders, indicating institutional interest in more targeted preventive tools for emerging, recurrent and endemic livestock diseases.
Market Challenges
Long Regulatory Approval Cycles
- A generic modern chemical veterinary drug can require 120 business days (2025 service standard, Thailand) when the dossier is complete. Portfolio expansion therefore requires early registration planning and disciplined regulatory project management.
- The regulatory structure differentiates at least 2 modern veterinary medicine categories (2025, Thailand), chemical medicines and biologics. Different evidence and review requirements increase execution complexity for multi-category suppliers and raise the value of specialist regulatory capabilities.
- Veterinary vaccines face 1 additional lot-release control before distribution (2025, Thailand) under biologics oversight. The requirement increases the operational importance of batch planning, regulatory documentation and safety-stock management for import-led vaccine portfolios.
Antimicrobial Stewardship Compresses Routine Antibiotic Volume
- The reduction materially exceeded the government's original 30% animal-use reduction target (2025 review, Thailand). Manufacturers relying heavily on routine antibiotics face portfolio pressure, while vaccines, diagnostics-linked treatment and targeted therapies gain relative strategic value.
- Human antibiotic use declined by 26% in the same national review (2025, Thailand), demonstrating that stewardship is part of a broad One Health policy direction rather than a temporary livestock-specific intervention.
- Thailand's AMR-system capability improved from 3.0 to 4.2 out of 5 (2025 review, Thailand). Stronger surveillance and governance increase compliance expectations and favor pharmaceutical suppliers with stewardship-oriented positioning and evidence-based use protocols.
Import Dependence and Cold-Chain Exposure
- The United States supplied approximately USD 53.1 million (2024, Thailand) of the relevant vaccine-class imports. Concentration in overseas production exposes distributors to freight, foreign-exchange, lead-time and batch-release risk.
- The Netherlands supplied approximately USD 28.9 million (2024, Thailand), highlighting the importance of European biologics manufacturing to Thai availability. Disruptions can therefore affect safety-stock requirements and working-capital intensity.
- Spain supplied approximately USD 20.7 million (2024, Thailand) of the same import category. Multi-country sourcing reduces single-supplier exposure but requires robust temperature-controlled logistics, registration maintenance and inventory forecasting across portfolios.
Market Opportunities
Premium Companion Biologics and Specialty Therapeutics
- Family-style pet care spending intensity is approximately 6 times traditional pet-keeping levels (2025, Thailand). This widens willingness to pay for preventive vaccines, chronic therapies and branded specialty medicines, benefiting manufacturers and veterinary hospital channels.
- Bangkok Metropolitan Region contained about 310,000 owned pets (2025, Thailand), around 6% of the national owned-pet population. Concentrated purchasing power creates an efficient launch market for premium veterinary products and specialist-clinic portfolios.
- An independent pet-medicine benchmark identifies biologics as the fastest-growth product class within a USD 117 million market (2025, Thailand). Capturing this opportunity requires clinic education, reliable cold-chain distribution and disease-specific companion-animal positioning.
Preventive Vaccine Portfolio Localization
- FMD management must address 3 virus types present in Thailand (2025, Thailand). Local formulation, filling, packaging or strategic stockholding can shorten replenishment cycles and support disease-specific availability without requiring complete upstream biologics localization.
- Routine cattle FMD boosters recur every 6 months (2025 protocol, Thailand). Predictable dosing cycles improve demand visibility, allowing manufacturers, distributors and investors to build capacity plans around recurring preventive consumption rather than episodic treatment demand.
- Autogenous-vaccine development attracted 120 public and private participants (2025, Thailand). Commercialization requires product standards, regulatory clarity and manufacturing capability, but it can create higher-value disease-specific solutions while reducing reliance on broad antibiotic use.
Provincial Technical-Service and Distribution Expansion
- Livestock Region 3 contained 544,403 beef-cattle farmers (2025, Thailand), representing 39.76% of the national beef-farmer base. Dense field coverage can improve product availability, dosing compliance and technical-sales productivity.
- Livestock Region 4 contained 398,264 beef-cattle farmers (2025, Thailand), equivalent to 29.08% of the national base. Distributor partnerships and mobile veterinary support can monetize this concentration without requiring fully owned provincial infrastructure.
- Livestock Region 3 held approximately 3.12 million beef cattle (2025, Thailand), or 32.73% of national stock. Suppliers able to combine inventory, vaccination scheduling and field technical support can capture more recurring revenue per customer relationship.
CHAPTER 9 - Competitive Landscape
Competitive Landscape Overview
Competition combines multinational animal-health portfolios with domestic manufacturers and specialist suppliers. Entry barriers arise from product registration, biologics cold-chain requirements, technical field support and nationwide farm or clinic access.
Market Share Distribution
Top 5 Players
Market Dynamics
8 new entrants in the past 5 years, indicating strong market attractiveness and growth potential.
Company Name | Market Share | Headquarters | Founding Year | Core Market Focus |
|---|---|---|---|---|
Zoetis (Thailand) Limited | - | Bangkok, Thailand | - | Companion and livestock vaccines, anti-infectives, parasiticides and therapeutics |
Boehringer Ingelheim Animal Health (Thailand) Ltd. | - | Bangkok, Thailand | - | Livestock and companion-animal vaccines, parasiticides and therapeutics |
Intervet (Thailand) Co., Ltd. (MSD Animal Health) | - | Bangkok, Thailand | - | Veterinary vaccines, therapeutic medicines and parasiticides |
Elanco (Thailand) Ltd. | - | Bangkok, Thailand | - | Livestock and companion-animal pharmaceuticals and preventive health products |
Ceva Animal Health (Thailand) Ltd. | - | Bangkok, Thailand | - | Veterinary vaccines and pharmaceuticals with poultry and companion-animal focus |
Virbac (Thailand) Co., Ltd. | - | Nonthaburi, Thailand | - | Companion and livestock therapeutic pharmaceutical portfolios |
Animal Health (Thailand) Co., Ltd. (HIPRA) | - | Bangkok, Thailand | - | Preventive animal health, veterinary vaccines and biologics |
Better Pharma Co., Ltd. | - | Bangkok, Thailand | 1978 | Domestic animal-health product manufacturing and veterinary pharmaceuticals |
Bioscience Animal Health Co., Ltd. | - | Nonthaburi, Thailand | - | Veterinary pharmaceuticals and animal-health product supply |
Advance Pharma Co., Ltd. | - | Bangkok, Thailand | - | Local veterinary pharmaceutical and animal-health product supply |
Cross Comparison Parameters
The report provides detailed cross-comparison of key players across 10 performance parameters to identify competitive strengths and weaknesses.
Analysis Covered
Market Share Analysis:
Benchmarks competitive scale using disclosed local revenue and portfolio evidence.
Cross Comparison Matrix:
Compares portfolio, channel, operating, and financial capabilities across verified players.
SWOT Analysis:
Assesses regulatory, portfolio, localization, channel, and innovation advantages by company.
Pricing Strategy Analysis:
Evaluates vaccine, therapeutic, tender, clinic, and distributor pricing approaches comparatively.
Company Profiles:
Maps verified Thailand presence, headquarters, portfolio focus, and competitive role.
CHAPTER 10 - REPORT TOC
Market Report Structure
Comprehensive coverage across three strategic phases - Market Assessment, Go-To-Market Strategy, and Survey - delivering end-to-end insights from market analysis and execution roadmap to customer demand validation.
Phase 1Market Assessment Phase
11
Chapters
Supply-side and competitive intelligence covering market sizing, segmentation, competitive dynamics, regulatory landscape, and future forecasts.
Phase 2Go-To-Market Strategy Phase
15
Chapters
Entry strategy evaluation, execution roadmap, partner recommendations, and profitability outlook.
Complete Report Coverage
201+ detailed sections covering every aspect of the market
143
Assessment Sections
58
Strategy Sections
CHAPTER 11 - Our Approach
Research Methodology
Desk Research
- Reviewed veterinary drug registration pathways
- Mapped livestock species demand indicators
- Analyzed veterinary vaccine trade flows
- Benchmarked animal-health supplier participation
Primary Research
- Animal-health commercial directors interviewed nationally
- Veterinary regulatory affairs managers consulted
- Livestock technical-service veterinarians interviewed
- Veterinary hospital procurement heads consulted
Validation and Triangulation
- 250 stakeholder responses triangulated across channels
- Supplier revenues reconciled against portfolios
- Species demand proxies checked independently
- Forecast closure tested across scenarios
CHAPTER 12 - FAQ
FAQs
Still have questions?
Our research team is here to help you find the right solution
CHAPTER 13 - Related Research
Explore Related Reports
Expand your market intelligence with complementary research across regions and adjacent markets.
Regional/Country ReportsRelated market analysis across key regions
Related market analysis across key regions
- Malaysia Veterinary Pharmaceuticals Market Size, Share & Forecast, By Product Type, Animal Type & Distribution Channel, 2025-2032
- Australia Veterinary Pharmaceuticals Market Size, Share & Forecast, By Product Type, Animal Type & Distribution Channel, 2025–2032
- New Zealand Veterinary Pharmaceuticals Market Report Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030
- Japan Veterinary Pharmaceuticals Market Report Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030
- Bahrain Veterinary Pharmaceuticals Market Report Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030
Adjacent ReportsRelated markets and complementary research
Related markets and complementary research
- South Korea Veterinary Diagnostic Equipment Market
- UAE Animal Feed Additives Market Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030
- Philippines Pet Nutrition Products Market
- South Korea Companion Animal Care Market
- Egypt Vaccination Supply Chain Market
500+
Market Research Reports
50+
Countries Covered
15+
Industry Verticals